We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GMAT3:BMFBOVESPAGrupo Mateus SA Analysis

Data as of 2026-06-06 - not real-time

R$4.08

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Grupo Mateus is trading at R$4.08, comfortably below its 20‑day SMA of R$4.28 and well under the 50‑day (R$4.46) and 200‑day (R$5.41) averages, confirming a bearish technical backdrop. The RSI at 40 and a bearish MACD histogram reinforce downside pressure, while volume is trending lower, suggesting limited buying interest. Recent earnings disclosed a miss on both EPS and revenue forecasts for Q1 2026, adding short‑term disappointment to the price action. Despite the technical weakness, the stock appears dramatically undervalued: the DCF‑derived fair value of R$11.96 implies a potential upside of roughly 69 %. Fundamental ratios are attractive, with a trailing PE of 5.2, a price‑to‑book below 1, and a dividend yield of 6.11% supported by a modest payout ratio of 24%. The company generates solid operating cash flow and carries a manageable debt‑to‑equity of 55.8%, indicating capacity to sustain its dividend. Consumer‑cyclical exposure in Brazil adds medium‑level geographic and sector risk, but the low beta (~0.5‑0.85) tempers market volatility. Overall, the market’s extreme greed sentiment (Fear‑Greed Index 83) may be overlooking the disconnect between price and intrinsic value, creating a compelling entry point for patient investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term moving averages and bearish MACD
  • Recent earnings miss and decreasing volume
  • High dividend yield provides downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation gap vs DCF fair value
  • Attractive PE, PB and dividend yield
  • Improving cash flow coverage of debt and dividend

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustained undervaluation with upside potential >60%
  • Stable dividend policy and low payout ratio
  • Resilient fundamentals despite cyclical sector exposure

Key Metrics & Analysis

Financial Health

Revenue Growth12.90%
Profit Margin4.49%
P/E Ratio5.2
ROE16.01%
ROA6.03%
Debt/Equity55.78
P/B Ratio0.9
Op. Cash FlowR$2.1B
Free Cash FlowR$1.4B

Technical Analysis

TrendBearish
RSI40.4
SupportR$4.06
ResistanceR$4.64
MA 20R$4.28
MA 50R$4.46
MA 200R$5.41
MACDBearish
VolumeDecreasing
Fear & Greed Index83.02

Valuation

Fair ValueR$11.96
Target PriceR$6.90
Upside/Downside69.12%
GradeUndervalued
TypeValue
Dividend Yield6.11%

Risk Assessment

Beta0.85
Volatility50.98%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.